Invivyd, Inc.

IVVD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021
Operating Activities
Net Income $-52.5M $-169.9M $-198.6M $-241.3M $-226.8M
Depreciation & Amortization $755.0K $1.5M $480.0K — —
Depreciation — — $480.0K $41.0K $1.0K
Amortization — — — — —
Stock-Based Compensation $11.6M $19.8M $18.7M $21.6M $17.8M
Net Cash from Operating Activities $-58.1M $-170.5M $-173.2M $-220.0M $-184.7M
Investing Activities
Capital Expenditures $155.0K $140.0K $615.0K $1.7M $84.0K
Business Acquisitions — — — — —
Net Cash from Investing Activities $-155.0K $-140.0K $280.7M $-230.7M $-50.7M
Financing Activities
Dividends Paid — — — — —
Stock Repurchases — $0 $1.0K $4.0K $0
Net Cash from Financing Activities $215.6M $39.3M $1.0M $506.0K $662.7M
Net Change in Cash $157.3M $-131.3M $108.6M $-450.1M $427.2M
Free Cash Flow $-58.3M $-170.6M $-173.8M $-221.7M $-184.8M